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Background: Elicitors and symptoms of anaphylaxis are age dependent. However, little
is known about typical features of anaphylaxis in patients aged 65 years or more.
Methods: The data from the Network for Online Registration of Anaphylaxis (NORA)
considering patients aged ≥65 (elderly) in comparison to data from adults (18–64 years)
regarding elicitors, symptoms, comorbidities, and treatment measures were analyzed.
Results: We identified 1,123 elderly anaphylactic patients. Insect venoms were the
most frequent elicitor in this group (p < 0.001), followed by drugs like analgesics
and antibiotics. Food allergens elicited less frequently anaphylaxis (p < 0.001). Skin
symptoms occurred less frequently in elderly patients (77%, p < 0.001). The clinical
symptoms were more severe in the elderly (51% experiencing grade III/IV reactions),
in particular when skin symptoms (p < 0.001) were absent. Most strikingly, a loss
of consciousness (33%, p < 0.001) and preexisting cardiovascular comorbidity (59%,
p < 0.001) were more prevalent in the elderly. Finally, adrenaline was used in 30% of the
elderly (vs. 26% in the comparator group, p < 0.001) and hospitalization was more often
required (60 vs. 50%, p < 0.001).
Discussion and Conclusion: Anaphylaxis in the elderly is often caused by
insect venoms and drugs. These patients suffer more often from cardiovascular
symptoms, receive more frequently adrenaline and require more often hospitalization.
Aurich et al. Anaphylaxis in Elderly
The data indicate that anaphylaxis in the elderly tends to be more frequently life
threatening and patients require intensified medical intervention. The data support the
need to recognize anaphylaxis in this patient group, which is prone to be at a higher risk
for a fatal outcome.
Keywords: anaphylaxis, elderly, insect venom, drug hypersensitivity, adrenaline, hospitalization, loss of
consciousness
INTRODUCTION
The incidence of anaphylaxis, which may occur at any age,
is rising in Western countries (1, 2). While life expectancy is
increasing, little is known about the characteristics of anaphylaxis
in elderly patients (3). Existing data indicate age dependent
differences with regard to elicitors, cofactors, and symptoms of
anaphylaxis (4).
Overall, elderly patients have a higher risk for severe and fatal
reactions (5).
The main elicitors of anaphylaxis are insect venoms, drugs
and food items (6). While food items are the most frequent
elicitors in children and young adults (7), drug anaphylaxis is
more common in elderly patients (8). Patients above 65 were
reported to be prone to develop cardiovascular symptoms more
frequently (9). It is unknown whether this is due to the increased
prevalence of cardiovascular diseases in this age group leading
to limited cardiovascular compensation mechanisms (10), use of
cardiovascular drugs (5), or both. Cofactors like exercise, drugs,
alcohol, and stress are supposed to reduce the threshold of allergic
reactions (11).
Recommendations for the emergency treatment of
anaphylaxis are similar for all age groups and are supported
by current guidelines (12). Some considerations and adaptions
should be made in elderly patients. Although, the administration
of adrenaline in anaphylactic patients with known or suspected
cardiovascular diseases is not contraindicated, it might
sometimes cause difficulties due to an increased coronary
blood flow e.g., in patients with acute coronary syndrome (10).
However, current guidelines clearly state that the benefit of
adrenaline usage outweighs its risks through beneficial effects
even in suspected anaphylaxis (12).
In this study, we analyzed data from adult patients
differentiated by age from the European Anaphylaxis Registry
registered between 2007 and 2017. The aim was to better
understand anaphylaxis in patients ≥65 years. Data regarding




The European Anaphylaxis Registry collects information on
anaphylactic reactions through a web based electronic data
capture system as described previously (6). Participation of
study centers is voluntary. Data for the current analysis were
Abbreviations: ICU, Intensive Care Unit.
provided by tertiary referral centers specialized in allergology
and/or dermatology in Germany, Switzerland, France, Austria,
Spain, Italy, Bulgaria, and Poland. The study was approved by
the Ethics Committee at Charité-Universitätsmedizin Berlin (the
coordinating center) and by the local Ethics Committees.
Data Source and Handling
After completion of diagnostics, patients’ data were retrieved
from medical treatment, laboratory measurements, and
emergency protocols as available. Using a pseudonym, the
data were entered by trained study personnel into an online
questionnaire in each study center. The questionnaire and data
entry is described elsewhere (7). Data collected from July 2007 to
March 2017 were included.
Variables
Age at reaction was categorized in two groups: patients aged 18–
64 years (adults), and patients 65 years and older (elderly). The
gathered variables are described elsewhere (7).
Statistical Analysis
The analysis of the data was carried out using R. The Shapiro-
Wilk’s test was used to assess the normality of distribution of
interval variables. Interval variables were expressed as mean ±
standard deviation. Distribution of categorical variables were
expressed as percentages. Differences in categorical variables
were tested using pairwise Chi2 tests with Holm’s correction
for multiple comparisons. The values P < 0.05 were considered
statistically significant.
RESULTS
The European Anaphylaxis Registry collected data of 10,203 cases
between July 2007 and March 2017. Six thousand eight hundred
ninety-one patients met the criteria of Ring andMessmer≥grade
II and were aged ≥18 years. The cases were registered from
78 study centers in seven countries: Germany (n = 4,474),
Switzerland (n = 777), France (n = 529), Austria (n = 461),
Spain (n = 267), Italy (n = 188), Bulgaria (n = 100), and Poland
(n= 95).
Of the 6,891 cases, 5,768 were adults younger than 65 years
and 1,123 were ≥65 years old (Figures 1, 2). The median age
in elderly patients was 70 (65–93) years and 95% of the cases
are between 65 and 80 years (Figure 2B). In general, both adult
groups comprised more females than males, but the elderly
included a higher percentage of male patients in comparison to
the comparator adult group (p= 0.005, Table 1).
Frontiers in Immunology | www.frontiersin.org 2 April 2019 | Volume 10 | Article 750
Aurich et al. Anaphylaxis in Elderly
FIGURE 1 | Flow chart of study cohort.
FIGURE 2 | Age distribution among adults (A) and the elderly (B).
The recent medical history in elderly patients is characterized
by significantly more frequent cardiovascular diseases, thyroid
and malignant diseases than in younger adults. In contrast, in
the younger adult group, atopic diseases were significantly more
common than in the elderly (p < 0.001).
Potential cofactors of any type (Table 1) were significantly
more prevalent in elderly patients (p < 0.001) and there was a
considerable association between the age and the concomitant
drug intake, under which ace inhibitor, AT-2 antagonist, beta-
blocker, acetylcholine, and proton pump inhibitor were taken
into account (Table 1; p < 0.001). Twenty-eight percentage of
elderly patients reported a previous allergic reaction to the same
elicitor. Of these 75% reported a previous milder reaction, 19%
had a similar or even more severe reaction (data not shown).
Insect Venom and Drugs Are Main Causes
of Anaphylaxis in the Elderly
Elicitors weremore frequently identified in the elderly (79%) than
in the younger adult group (74%; p < 0.001; Table 2). Insect
venom anaphylaxis was most prevalent in elderly patients (n =
633; 56%; p < 0.001), with yellow jacket (n = 451, 71%) being
the cause in the majority of cases. Drugs were the second main
causative agent of anaphylaxis across adults again being more
prevalent in the elderly (25%; p= 0.009). Analgesics [metamizole
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n (%) n (%) Chi2 test
TOTAL 1,123 (16) 5,768 (84)
Median age in years (min–max) 70 (65–93) 45 (18–64)
Male 517 (46) 2,394 (42) p = 0.005
COMORBIDITIES
Atopic 190 (18) 1,628 (30) p < 0.001
Cardiovascular 641 (60) 960 (18) p < 0.001
Mastocytosis 39 (4) 136 (3) NS (p =
0.051)
Thyroid 162 (15) 476 (9) p < 0.001
Urticaria 14 (1) 104 (2) NS
Malignant disease 63 (6) 97 (2) p < 0.001
COFACTORS
Overall 802 (71) 2,897 (54) p < 0.001
Drugs# 614 (57) 991 (18) p < 0.001
Physical exercise 267 (27) 1,609 (31) p = 0.02
Psychological stress 84 (8) 418 (7) NS
Alcohol 48 (5) 326 (7) NS (p =
0.051)
Acute Infection 33 (3) 177 (3) NS
SEVERITY ACCORDING TO RING&MESSMER
Grade II 550 (49) 3,505 (61) p < 0.001
Grade III 525 (47) 2,105 (37) p < 0.001
Grade IV 48 (4) 158 (3) p = 0.023
In total 6,891 cases ≥18 years old were analyzable until March 2017. Statistical
calculations were performed with chi2 test including post-hoc corrections. Significant
differences were given in comparison to adults between 18 and 64 years of age.
#Drugs counted as cofactors were ace-inhibitor, AT-2-antagonist, beta-blocker,
acetylcholine, and proton pump inhibitor.
(n = 19; 7%), diclofenac (n =45; 16%), ibuprofen (n = 17; 6%)]
and antibiotics [penicillin (n = 23; 8%), cephalosporins (n = 30;
11%), gyrase inhibitors/ quinolones (n = 14; 5%)] were the most
frequent single elicitors of drug anaphylaxis in the elderly. Food
was a predominant elicitor in adults (22%, p< 0.001; Table 2). In
the elderly only 11% of reactions were caused by food, with wheat
(14%) and hazelnut (13%) as leading food allergens.
Cardiovascular Symptoms Predominate in
the Elderly
Cardiovascular symptoms occurred frequently in elderly patients
(80% compared to adults 75%; p< 0.001). Amajor cardiovascular
symptom was loss of consciousness (adults: 20%; elderly 33%, p
< 0.001) while dizziness and tachycardia were more prevalent
in adults (Figure 3D). Cardiac arrest occurred in 153 cases (3%
in elderly vs. 2% in adults). The skin was the most frequently
involved organ system of all affected patients. However, there
was a shift showing that elderly patients are less frequently
affected (77%) in comparison to younger adults (83%; p < 0.001;
Figure 3A). The severity of the reactions in elderly patients
without skin symptoms was increased in comparison to the






n (%) n (%) Chi2 test
TOTAL 1,123 (16%) 5,768 (84%)
Elicitor known 883 (79) 4,242 (73) p < 0.001
INSECTS 633 (56) 2,708 (47) p < 0.001
Yellow jacket 451 (71) 1,936 (72) NS
Bee 97 (15) 512 (19) NS
Hornet 56 (9) 153 (6) p < 0.001
DRUGS 285 (25) 1,257 (22) p = 0.009
Analgesics 103 (36) 354 (36) NS
Antibiotics 74 (26) 354 (28) NS
Local anesthetics 17 (6) 106 (8) NS
x-ray (contrast agent) 22 (8) 56 (4) P = 0.010
PPI 6 (2) 30 (2) NS
Cardiovascular drugs 5 (1.8) 8 (0.6) NS
FOOD 122 (11) 1,254 (22) p < 0.001
Wheat 17 (14) 177 (14) NS
Hazelnut 16 (13) 84 (7) p = 0.015
Shellfish 15 (12) 123 (10) NS
Celery 7 (6) 74 (6) NS
Soy 6 (5) 78 (6) NS
Peanut 1 (0.8) 68 (5) p = 0.045
IMMUNOTHERAPY (SIT) 5 (0.4) 63 (1.1) p = 0.006
The elicitor was not specified in 423 (6%) patients. Rare elicitors are not reported in detail.
Statistical analysis was performed with Chi2 test including post-hoc corrections.
Significant differences were given in comparison to adults between 18 and 64 years of
age. Food items reported <10 times in the whole study are not listed in detail. PPI, proton
pump inhibitor.
corresponding group of adults not suffering from skin symptoms
(p< 0.001, data not shown). Gastrointestinal symptoms occurred
in a similar proportion in both adult groups (Figure 3B).
The respiratory system was less frequently affected in the
elderly (63% compared to adults 70%; p < 0.001), especially
dyspnea (adults: 55%; elderly 51%; p < 0.001; Figure 3C). Severe
anaphylactic reactions including grade III (47%) and grade IV
(4%) anaphylaxis were more prevalent in the elderly (Table 1).
Increased Administration of Adrenaline in
the Elderly
First-line treatment was carried out by emergency physicians in
5,481 (92%) of 5,971 patients who received first-line treatment.
The administration rate of adrenaline by professionals in elderly
patients was 30 and 26% in younger adults (Figure S1, across
all severity grades; p = 0.043). Hospitalization was required in
60 and 19% of elderly patients were treated in an intensive
care unit (ICU) (Figure 4). Regardless the severity grade, the
hospitalization and the ICU admission rates were higher in the
elderly (p < 0.01).
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FIGURE 3 | (A–D) Frequency of selected symptoms according to age in adults.
FIGURE 4 | Hospitalization and intensive care unit admissions across the
severity grades according to Ring & Messmer; elderly (n = 1,123) and adults
(n = 5,768); ***p < 0.001, ns, not significant.
DISCUSSION
Key Results
This is the first large-scale analysis of anaphylactic patients
including 1,123 cases aged 65 years or more. The European
Anaphylaxis Registry covers a heterogenic sample of patients
across all age groups and a wide range of elicitors, from different
European countries (6, 13).
The most frequent elicitor in both adult groups was insect
venom, but elderly patients had significantly more insect elicited
cases than younger adults (56 vs. 47%). The data indicate
that the clinical reactivity to insect venoms increases with age,
although the individual exposure to insect stings might be
comparable among adults, whereas one could speculate that
retired elderly spend more time outdoor, e.g., in the garden.
However, supposing comparable exposure, one reason for this
observation might be the higher frequency of comorbidities,
which may enhance the clinical response pattern particularly in
patients with preexisting cardiovascular diseases increasing the
risks for severe cardiovascular symptoms like tachyarrhythmia
or syncope.
Moreover, we identified drugs as frequent elicitors in the
elderly. This finding is in line with previous data from the registry
and most likely associated with a higher drug intake in this
patient group (6, 14). Also, drug interaction maybe relevant
in this context. Another previous study analyzing patients ≥71
years identified males to be predisposed to develop insect sting
anaphylaxis whereas females suffered more often from drug
anaphylaxis (15).
Furthermore, the distribution of elicitors differ by country (6).
This observation is also reflected in the elderly patient group from
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different countries, e.g., drugs were the most frequent elicitors in
Bulgaria and Spain and not insect venoms (data not shown).
The skin is the most frequently involved organ system
in anaphylaxis as shown by many different studies including
our own data (6). Most interestingly, the occurrence of skin
symptoms in the elderly was significantly reduced compared
to the younger adults. Moreover, this lack of skin symptoms
was associated with more severe anaphylaxis in the group
of the elderly patients. This phenomenon has been described
previously and been attributed to the fast development of a severe
circulatory impairment (16). Another assumption regarding the
lack of skin symptoms and the onset of a severe reaction might
be a delay of the diagnosis. A lack of skin symptoms leads
to a significant reduced identification rate of anaphylaxis and
consequently to delayed therapy (17). However, this would still
not explain why skin symptoms are less frequent in this patient
group, but may also be attributed to a decreased vascularization
of the skin in higher age groups. A final hypothesis might be
the intake of drugs affecting skin reactivity like betablockers
or neuroleptics.
Cardiovascular manifestations of anaphylaxis occurred more
frequently in our elderly patient cohort. Most interestingly,
loss of consciousness was the predominant symptom in this
patient group and has been observed by us in a previous
analysis (18). Considering the overall adult cohort, most patients
suffering from cardiovascular symptoms presented with dizziness
and hypotension.
Adrenaline is the first treatment of choice in anaphylaxis and
recommended by several international guidelines (12). However,
data from others as well as our group indicate that most
patients are not treated according to guidelines. By contrast,
professional first-line treatment frequently includes the use of
corticosteroids and antihistamines but less frequently adrenaline,
especially in Germany (19). The data from this study show a
significant impact of an increased age and the higher usage
rate of adrenaline among all severity grades of the reaction.
This finding is striking considering the fact that the group of
elderly patients suffered more frequently from cardiovascular
diseases and took more concomitant medication (10). The higher
usage of adrenaline in the elderly might also be due to the
higher percentage of patients experiencing grade IV reactions,
since adrenaline is often used in cardiopulmonary resuscitation.
Even though adrenaline was applied more often in the elderly
than in younger adults investigated here, still <1 out of three
patients received adrenaline as first line treatment. Adrenaline
was mostly applied intravenously by professionals in the elderly
(data not shown) not fulfilling the recommendations of the
current guidelines for the management of anaphylaxis (12).
The administration of intramuscular adrenaline is the route of
first choice, because the risk of cardiovascular side effects is
considerably lower (20).
This data indicate the need of educational measures regarding
the acute treatment of anaphylaxis not only among patients but
also among professionals. In particular, in emergency medical
professionals the recognition of barriers against the use of
adrenaline by an intramuscular route requires more attention.
Recently, also guidelines from the resuscitation council are in
favor of the first line intramuscular route and are an important
step forward to change current clinical practice (21).
Finally, we observed increased hospital admission rates and
treatment in ICU in elderly patients. Such an observation has
been reported in previous studies from the US (9, 22). Most
studies explain this phenomenon attributed to more severe
reactions in elderly patients (8). However, our data suggest,
that the hospital and the ICU admission rate was significantly
higher in the elderly independent from the severity grade
of anaphylaxis. Therefore, we propose that mostly due to
comorbidities the patients are more often hospitalized, whether
biphasic anaphylaxis occurs more frequently in the elderly
patients is not known, but should be analyzed in more detail in
future studies.
Strength and Limitations
We report on a large group of elderly European anaphylactic
patients covering a 10-year observational period. The web-
based assessment tool for registration covers several aspects
of an anaphylactic reaction in a standardized manner,
including elicitors, symptoms, co-factors, and emergency
treatment. The online questionnaire was consistently revised and
piloted (6).
The data are limited to patient records and not representative
for a population as only patients are registered when seen for an
allergy assessment after a given reaction.
CONCLUSION
In this large-scale description of anaphylaxis in patients aged
65 years and older, we report on characteristic age-dependent
elicitors, comorbidities, symptoms, and emergency treatment.
Features of anaphylaxis in patients aged 65 or more years
differ from those of the younger adult group. The elderly
are more likely to have anaphylaxis without skin symptoms
which is associated with more difficulties to make diagnosis of
anaphylaxis and more severe reactions. Moreover, the risk for
insect venom anaphylaxis raises with age. The hospitalization and
ICU admission rate were higher in elderly patients independent
from the severity grade indicating that such patients require
intensified medical intervention.
This study is one of the first comprehensive studies on patients
≥65 years who experienced anaphylaxis. It contributes to a better
management and identification of specific medical needs in an
aging population.
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